| DATE of Therapy |
WEEK NO |
DAY OF WEEK |
Treatment |
| 01~04 |
1`2 |
6、7、1、2、3 |
IL-2 200,000U IM QD for TLC motion into Circulation
|
| 05 |
2 |
4 |
Rest |
| 06 |
2 |
5 |
COLLECT BLOOD for PBMC Culture IN Vitro |
| 07~10 |
2~3 |
6、7、1、2 |
REST(With IL-2、PHA、GM-CSF culture PBMC to produce
CTL,LAK and APC) |
| 11 |
3 |
3 |
First reinfusion of LAK(+APC) |
| 12 |
3 |
4 |
IL-2 200,000U IM QD for maintain the hiher antivial
activity of LAK |
| 13 |
3 |
5 |
Second reinfusion of LAK(+APC) |
| 14~15 |
3 |
6-7 |
IL-2 200,000U IM QD for maintain the hiher antivial
activity of LAK |
| 16 |
4 |
1 |
Third reinfusion of LAK(+APC) |
| 17 |
4 |
2 |
IL-2 200,000U IM QD for maintain the hiher antivial
activity of LAK |
| 18 |
4 |
3 |
Foutrh reinfusion of LAK(+APC) |
| 19 |
4 |
4 |
IL-2 200,000U IM QD for maintain the hiher antivial
activity of LAK |
| 20 |
4 |
5 |
Fifth reinfusion of LAK(+APC) |
| 21~22 |
4 |
6-7 |
IL-2 200,000U IM QD for maintain the hiher antivial
activity of LAK |
| 23 |
5 |
1 |
Sixth reinfusion of LAK(+APC) |
| 24 |
5 |
2 |
IL-2 200,000U IM QD for maintain the hiher antivial
activity of LAK |
| 25 |
5 |
3 |
Seventh reinfusion of LAK(+APC) |
| 26 |
5 |
4 |
IL-2 200,000U IM QD for maintain the hiher antivial
activity of LAK |
| 27 |
5 |
5 |
Eighth reinfusion of LAK(+APC) |
| 28~29 |
5 |
6-7 |
IL-2 200,000U IM QD for maintain the hiher antivial
activity of LAK |
| 30 |
6 |
1 |
Ninth reinfusion of LAK(+APC) |